These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34034559)

  • 1. Construction of enzalutamide-resistant cell model of prostate cancer and preliminary screening of potential drug-resistant genes.
    Feng T; Wei D; Zhao J; Li Q; Guo P; Yang X; Li M; Jiang Y; Luo Y
    Exp Biol Med (Maywood); 2021 Aug; 246(15):1776-1787. PubMed ID: 34034559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer.
    Verma S; Shankar E; Chan ER; Gupta S
    Cells; 2020 Nov; 9(12):. PubMed ID: 33255236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer.
    Yoshida S; Kajiwara D; Seki M; Tayama M; Tanaka Y; Mizutani H; Fujita R; Yamamura K; Okajima S; Asai M; Minamiguchi K
    Mol Oncol; 2024 Aug; 18(8):1980-2000. PubMed ID: 38600681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway.
    Chen X; Yang G; Liu M; Quan Z; Wang L; Luo C; Wu X; Zheng Y
    Biochem Biophys Res Commun; 2022 Jul; 613():53-60. PubMed ID: 35533600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
    Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
    Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
    Coleman DJ; Van Hook K; King CJ; Schwartzman J; Lisac R; Urrutia J; Sehrawat A; Woodward J; Wang NJ; Gulati R; Thomas GV; Beer TM; Gleave M; Korkola JE; Gao L; Heiser LM; Alumkal JJ
    Oncotarget; 2016 Jun; 7(26):40690-40703. PubMed ID: 27276681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
    Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
    Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
    Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT).
    Choi JD; Kim TJ; Jeong BC; Jeon HG; Jeon SS; Kang MY; Yeom SY; Seo SI
    Sci Rep; 2021 Nov; 11(1):21984. PubMed ID: 34753990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells
    Kohrt SE; Awadallah WN; Phillips RA; Case TC; Jin R; Nanda JS; Yu X; Clark PE; Yi Y; Matusik RJ; Anderson PD; Grabowska MM
    Mol Cancer Ther; 2021 Feb; 20(2):398-409. PubMed ID: 33298586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures.
    Sha K; Yeh S; Chang C; Nastiuk KL; Krolewski JJ
    Oncotarget; 2015 Sep; 6(28):25726-40. PubMed ID: 26327448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
    Armstrong CM; Liu C; Liu L; Yang JC; Lou W; Zhao R; Ning S; Lombard AP; Zhao J; D'Abronzo LS; Evans CP; Li PK; Gao AC
    Clin Cancer Res; 2020 Nov; 26(22):6064-6074. PubMed ID: 32928794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
    J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance.
    Li C; Lanman NA; Kong Y; He D; Mao F; Farah E; Zhang Y; Liu J; Wang C; Wei Q; Liu X
    J Biol Chem; 2020 Apr; 295(16):5470-5483. PubMed ID: 32184358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
    Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Long Noncoding RNA
    Ghildiyal R; Sawant M; Renganathan A; Mahajan K; Kim EH; Luo J; Dang HX; Maher CA; Feng FY; Mahajan NP
    Cancer Res; 2022 Jan; 82(1):155-168. PubMed ID: 34740892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
    Li S; Fong KW; Gritsina G; Zhang A; Zhao JC; Kim J; Sharp A; Yuan W; Aversa C; Yang XJ; Nelson PS; Feng FY; Chinnaiyan AM; de Bono JS; Morrissey C; Rettig MB; Yu J
    Cancer Res; 2019 May; 79(10):2580-2592. PubMed ID: 30952632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
    Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
    Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer.
    Farah E; Zhang Z; Utturkar SM; Liu J; Ratliff TL; Liu X
    Mol Cancer Ther; 2022 Jan; 21(1):193-205. PubMed ID: 34728570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.